Readmission with respiratory syncytial virus (RSV) infection among graduates from a Neonatal Intensive Care Unit
暂无分享,去创建一个
[1] A. Milner,et al. Respiratory status and allergy nine to 10 years after acute bronchiolitis , 1997, Archives of disease in childhood.
[2] G. Escobar,et al. Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm Infants , 1999, Pediatrics.
[3] M. Beresford,et al. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort , 2000, Archives of disease in childhood.
[4] B. Kjellman,et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. , 2000, American journal of respiratory and critical care medicine.
[5] B. Melegh,et al. Urinary glycosaminoglycan excretion in urolithiasis , 2000, Archives of disease in childhood.
[6] T. Powers,et al. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. , 2000, The Pediatric infectious disease journal.
[7] M. Sharland,et al. Preventing respiratory syncitial virus bronchiolitis , 2001, BMJ : British Medical Journal.